Part of ANZGOG’s OASIS initiative, iPRIME is the first ANZGOG-initiated study in the first-line setting of ovarian cancer, involving a treatment intervention, led by Assoc Prof Tarek Meniawy.
Assoc Prof Tarek Meniawy, iPRIME’s Chief Principal Investigator
iPRIME is a Phase II study of durvalumab and tremelimumab in combination with neoadjuvant carboplatin and paclitaxel in newly diagnosed women with advanced high grade serous ovarian, fallopian tube and peritoneal cancers.
As iPRIME approaches the end of recruitment, with 68 patients registered to the study to date and only 4 positions left – Chief Principal Investigator, Assoc Prof Tarek Meniawy would like to thank all the women who have taken part in the study so far. Despite the length of the treatments, these women have been so generous with their time, and without the ongoing commitment of participants, these trials would not be possible.
“I’m looking forward to the results of the study that will enable us to understand how safe and effective the combination of immunotherapy with standard platinum-based chemotherapy is in patients with ovarian, fallopian tube and peritoneal cancers. The results from the translational sub-study, TRiPRIME will also provide greater insights into the patients that would most likely benefit from this novel combination therapy.”
The iPRIME trial is currently recruiting from the following sites:
- Linear Clinical Research – WA
- St John of God Subiaco Hospital – WA
- Newcastle Private Hospital – NSW
- Prince of Wales Hospital – NSW
- Westmead Hospital – NSW
- Royal Brisbane & Women’s Hospital – QLD
- Mater Brisbane Hospital – QLD
- Peter MacCallum Cancer Centre – VIC
- Monash Medical Centre – VIC
If you believe that you may be a suitable candidate, please speak to your Medical Oncologist about your eligibility.
For more information, please click here.
